Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/11/20
End: 08/30/23
Due: 08/30/24
Phase: N/A
Priority: Normal
Start: 07/21/22
End: 09/01/23
Due: 09/01/24
Phase: N/A
Priority: Normal
Start: 01/01/21
End: 06/30/22
Due: 06/30/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial | NCT04531228 | Yunfei Yuan | user2@example.com | None | 2020-10-11 | 2023-08-30 | 2024-08-30 | - | - | 2025-07-14 |
| HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | NCT05290116 | Yunfei Yuan | user2@example.com | None | 2022-07-21 | 2023-09-01 | 2024-09-01 | - | - | 2025-07-14 |
| TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT | NCT05535998 | Yunfei Yuan | user2@example.com | None | 2021-01-01 | 2022-06-30 | 2023-06-30 | - | - | 2025-07-14 |